The European journal of health economics : HEPAC : health economics in prevention and care
-
Randomized Controlled Trial
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients. ⋯ Nivolumab is a cost-effective treatment for advanced melanoma patients in England.